FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 545 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin-Gemcitabine for the Treatment of Patients... June 15, 2023 OncoArray Links Dozens of DNA Variants to Risk for Common Cancers June 12, 2018 Welcome to Caring Connections November 18, 2020 Working Together to Choose a Cancer Treatment Plan: A Caregiver’s Perspective June 16, 2022 Load more HOT NEWS Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... Osteoblasts Are “Warrior” Bone Cells That Can Suppress Bone-Metastatic Breast Cancer... Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity...
